M. Curtis

Seizure outcome after epilepsy surgery in tuberous sclerosis complex: Results and analysis of predictors from a multicenter study

L. Tassi, C. Barba, A. Vignoli, 2021, Journal of the Neurological Sciences.

Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.

Rebecca A Miksad, Sean Khozin, Amy P Abernethy, 2018, The oncologist.

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.

A. Abernethy, S. Khozin, R. Pazdur, 2018, The oncologist.

Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record‐Derived Real‐World Data

C. Bennette, L. Bellomo, R. Miksad, 2021, Clinical pharmacology and therapeutics.

Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint

A. Abernethy, S. Griffith, Michael D. Taylor, 2018, Health Services Research.

Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations

Brian D. Segal, W. Katherine Tan, Elizabeth Garrett-Mayer, 2021, Contemporary clinical trials communications.

Opportunities and challenges in leveraging electronic health record data in oncology.

Amy P Abernethy, Marc L Berger, A. Abernethy, 2016, Future oncology.

Rates of PD-L1 expression testing in U.S. community-based oncology practices (USCPs) for patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab (N) or pembrolizumab (P).

A. Abernethy, S. Khozin, R. Pazdur, 2017 .